---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "oqVOgsFGaGpuiD371U0dtI2cxPyViYHEg6TqRvqAeFZrvoof/Jr9qJEHqx62OFI3YNluFOb+/UoykxUutdvTDRpa2uhEFprUr6ksxgoUkTc4/oxd54Ff1DBQpzH2TxExZcpnJhUbt1gaA3FFI6uBLUr7sCONs3jhxRT6CZJqQEAkHLWFzPHZPwlmMZTfrtn6qql67kDfEEnE0kWRB0jRtWO6QwgMeP0u/dUqZbhDB4SWu4Y9+0eRxzhh0xBYAWmCf3yFttjNNi5dh6CNgMSrjxt7fJ13S2jFNK1ZA2CHf/Vmjocwb4l45J2l4ugpBr6Zz/IJM771/J/BpSwKArDN0b0WZvdbJMECkEtBeXKdliE=;h08g8EzQSlXNSr1CSOCQ+Q=="
---

